Literature DB >> 2729314

Dosing of contrast material to prevent contrast nephropathy in patients with renal disease.

R G Cigarroa1, R A Lange, R H Williams, L D Hillis.   

Abstract

PURPOSE: Contrast-induced renal dysfunction has been reported to occur in 15% to 42% of patients with underlying azotemia, but there is disagreement as to whether its incidence is reduced by limiting the amount of contrast material. To adjust the amount of contrast material to the severity of azotemia, we have utilized the following formula to calculate a contrast material "limit" in patients with renal disease: Contrast material limit = (formula; see text) PATIENTS AND METHODS: Over a 10-year period, 115 patients (53 men, 62 women, aged 61 +/- 11 [mean +/- SD] years) with renal dysfunction (baseline serum creatinine level greater than or equal to 1.8 mg/dL) underwent cardiac catheterization and angiography, after which the level of serum creatinine was measured daily for five days. The amount of contrast material that was given adhered to the limit in 86 patients (Group I) and exceeded it in 29 (Group II).
RESULTS: Contrast-induced renal dysfunction (an increase in serum creatinine greater than or equal to 1.0 mg/dL) occurred in two (2%) patients in Group I and in six (21%) patients in Group II (p less than 0.001). Of the 48 patients with concomitant diabetes mellitus, the contrast limit was surpassed in 16, six (38%) of whom had contrast nephropathy. Only two of the 32 (6%) diabetic patients in whom the contrast limit was not exceeded had contrast nephropathy (p less than 0.001).
CONCLUSIONS: Thus, contrast-induced renal dysfunction occurs infrequently if the amount of contrast material is limited in accordance with the degree of azotemia. Diabetic patients have a high incidence of contrast nephropathy, particularly when they receive an excessive amount of contrast. In patients with diabetes and renal impairment, it may be preferable to perform angiography as a staged procedure or to utilize alternative (non-contrast) techniques to obtain the desired information rather than to exceed the prescribed contrast limit.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2729314     DOI: 10.1016/0002-9343(89)90437-3

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  103 in total

1.  Prolonged carotid sinus reflex is a risk factor for contrast-induced nephropathy following carotid artery stenting.

Authors:  T Kato; H Sakai; M Tsujimoto; Y Nishimura
Journal:  AJNR Am J Neuroradiol       Date:  2011-01-27       Impact factor: 3.825

2.  Use and efficacy of saline hydration and N-acetyl cysteine to prevent contrast-induced nephropathy in low-risk populations undergoing coronary artery angiography.

Authors:  Paolo Calabrò; Renatomaria Bianchi; Mario Crisci; Mario Caprile; Maurizio Cappelli Bigazzi; Rosalinda Palmieri; Enrica Golia; Anna De Vita; Ilaria Jane Romano; Giuseppe Limongelli; Maria Giovanna Russo; Raffaele Calabrò
Journal:  Intern Emerg Med       Date:  2011-01-29       Impact factor: 3.397

3.  Urine protein as a rapid screen for renal function in the ED: can it replace serum creatinine in selected patients?

Authors:  Jonathan Glauser; Aaron Montgomery
Journal:  Emerg Radiol       Date:  2004-05-05

Review 4.  Contrast-induced acute kidney injury: the at-risk patient and protective measures.

Authors:  Jeremiah R Brown; Craig A Thompson
Journal:  Curr Cardiol Rep       Date:  2010-09       Impact factor: 2.931

5.  Reducing Acute Kidney Injury Due to Contrast Material: How Nurses Can Improve Patient Safety.

Authors:  Peggy Lambert; Kristine Chaisson; Susan Horton; Carmen Petrin; Emily Marshall; Sue Bowden; Lynn Scott; Sheila Conley; Janette Stender; Gertrude Kent; Ellen Hopkins; Brian Smith; Anita Nicholson; Nancy Roy; Brenda Homsted; Cindy Downs; Cathy S Ross; Jeremiah Brown
Journal:  Crit Care Nurse       Date:  2017-02       Impact factor: 1.708

6.  Guidelines on the use of iodinated contrast media in patients with kidney disease 2012: digest version : JSN, JRS, and JCS Joint Working Group.

Authors:  Iwao Ohno; Hiromitsu Hayashi; Kazutaka Aonuma; Masaru Horio; Naoki Kashihara; Hirokazu Okada; Yasuhiro Komatsu; Shozo Tamura; Kazuo Awai; Yasuyuki Yamashita; Ryohei Kuwatsuru; Atsushi Hirayama; Yoshihiko Saito; Toyoaki Murohara; Nagara Tamaki; Akira Sato; Tadateru Takayama; Enyu Imai; Yoshinari Yasuda; Daisuke Koya; Yoshiharu Tsubakihara; Shigeo Horie; Yukunori Korogi; Yoshifumi Narumi; Katsumi Hayakawa; Hiroyuki Daida; Koichi Node; Isao Kubota
Journal:  Clin Exp Nephrol       Date:  2013-08       Impact factor: 2.801

7.  Guidelines on the use of iodinated contrast media in patients with kidney disease 2012: digest version. JSN, JRS, and JCS Joint Working Group.

Authors:  Iwao Ohno; Hiromitsu Hayashi; Kazutaka Aonuma; Masaru Horio; Naoki Kashihara; Hirokazu Okada; Yasuhiro Komatsu; Shozo Tamura; Kazuo Awai; Yasuyuki Yamashita; Ryohei Kuwatsuru; Atsushi Hirayama; Yoshihiko Saito; Toyoaki Murohara; Nagara Tamaki; Akira Sato; Tadateru Takayama; Enyu Imai; Yoshinari Yasuda; Daisuke Koya; Yoshiharu Tsubakihara; Shigeo Horie; Yukunori Korogi; Yoshifumi Narumi; Katsumi Hayakawa; Hiroyuki Daida; Koichi Node; Isao Kubota
Journal:  Jpn J Radiol       Date:  2013-08       Impact factor: 2.374

8.  Development of contrast-induced nephropathy in subarachnoid hemorrhage: a single center perspective.

Authors:  Bappaditya Ray; Kim L Rickert; Babu G Welch; Jonathan A White; Daniel R Klinger; Benjamin P Boudreaux; Brett A Whittemore; Eugene Gu
Journal:  Neurocrit Care       Date:  2013-10       Impact factor: 3.210

9.  Preventing contrast-induced nephropathy in patients with baseline renal dysfunction undergoing coronary angiography.

Authors:  Po-Tsang Lee; Kang-Ju Chou; Hua-Chang Fang
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-02

Review 10.  Contrast-induced acute kidney injury: specialty-specific protocols for interventional radiology, diagnostic computed tomography radiology, and interventional cardiology.

Authors:  Stanley Goldfarb; Peter A McCullough; John McDermott; Spencer B Gay
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.